When two year results of the RIO-North America (Rimonabant In Obesity) trial were presented at the American Heart Association (AHA) scientific meeting in New Orleans in November, researchers said additional results from studies underway could be expected by the end of the year.
But seven weeks have passed with no news on when additional data from clinical studies of the use of Acomplia in promoting weight loss or smoking cessation can be expected.
There also has been no recent update on whether the drug’s developer, Sanofi-Aventis, still plans to file for U.S. Food and Drug Administration approval in the second quarter of this year.
We recently asked Sanofi-Aventis when they next expected to report Acomplia results, and as of yet have received no reply.
At this point, there are three studies for which no data has been reported — one study of the role of rimonabant in improving risk factors related to diabetes and two studies of the value of Acomplia in aiding smoking cessation.
Метки:
clinical,
drug,
loss,
obesity,
report,
results,
smoking,
study,
weight,
Zimulti,
Новости
Посмотрите также
- Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
- Report: Many Seek Accomplia, But the Hype Exceeds What Is Known So Far
At obesity treatment centers, nearly every Acomplia (rimonabant) patient now asks for Acomplia (rimonabant), the New York Times reports. But many medical researchers, the newspaper found, say that while rimonabant may be intriguing, “the mythology in the making is hardly justified by what is known so far.
[...]
- Report in The Lancet Further Boosts Interest in Weight-Loss Drug Acomplia
A report published in this week’s issue of the prestigious medical journal, The Lancet, further stoked interest in the promising new weight-loss drug Acomplia (rimonabant) but in fact provided little new information.
The report was based on one-year results from the RIO-Europe clinical trial, which showed that Acomplia could substantially [...]
- Merck to Report Results for Taranabant, Acomplia Competitor, on Oct. 24th
Merck plans to deliver the first official report on results of trials of its new diet drug Taranabant — which like Sanofi’s rimonabant works by blocking CB-1 receptors — on Wednesday, October 24th, at The Obesity Society’s annual scientific meeting in New Orleans.
Dr. Ngozi Erondu, senior director of clinical research for [...]
- Encouraging Acomplia Results Greeted With Mix of Excitement and Caution
Highly encouraging results reported November 9th from the largest trial to date of the new diet drug Acomplia (rimonabant) were greated with a mixture of excitement and caution by the medical community.
Data from a two-year study of rimonabant showed the drug helped obese patients lose four times as much [...]
- Study: Acomplia Increases the Likelihood of Success in Quitting Smoking
Researchers at the University of Cincinnati Acomplia (rimonabant) College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared with placebo, markedly [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.